Masimo (MASI) Receives Coverage Optimism Rating of 0.19
News headlines about Masimo (NASDAQ:MASI) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Masimo earned a daily sentiment score of 0.19 on Accern’s scale. Accern also gave news stories about the medical equipment provider an impact score of 46.0453743307326 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the media headlines that may have impacted Accern’s analysis:
- StartUp Health Lands $19.3M to Help Startups Achieve Health Moonshots (hitconsultant.net)
- Chinese insurer invests in Startup Health’s $19M haul among other investors (medcitynews.com)
- Masimo to Present at 36th Annual J.P. Morgan Healthcare Conference (finance.yahoo.com)
- Masimo (MASI) Stock Rating Lowered by Zacks Investment Research (americanbankingnews.com)
- StartUp Health Raises $19.3M Led by Ping An Global Voyager Fund, GuideWell and Masimo (prweb.com)
Several equities analysts recently issued reports on the stock. Zacks Investment Research lowered shares of Masimo from a “buy” rating to a “hold” rating in a report on Wednesday. BidaskClub lowered shares of Masimo from a “hold” rating to a “sell” rating in a report on Thursday, December 7th. Finally, Stifel Nicolaus restated a “buy” rating and issued a $108.00 target price on shares of Masimo in a report on Friday, November 3rd. One investment analyst has rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $97.17.
Masimo (NASDAQ:MASI) last released its earnings results on Tuesday, October 31st. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.53 by $0.17. Masimo had a net margin of 45.83% and a return on equity of 22.17%. The business had revenue of $193.69 million for the quarter, compared to analyst estimates of $189.01 million. During the same quarter in the previous year, the business earned $0.52 earnings per share. Masimo’s revenue for the quarter was up 15.6% on a year-over-year basis. equities research analysts anticipate that Masimo will post 2.95 EPS for the current year.
In other Masimo news, Director Steven Barker sold 10,000 shares of Masimo stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $90.00, for a total value of $900,000.00. Following the completion of the sale, the director now directly owns 73,249 shares of the company’s stock, valued at $6,592,410. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Yongsam Lee sold 5,000 shares of Masimo stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $89.89, for a total transaction of $449,450.00. Following the completion of the sale, the executive vice president now directly owns 74,000 shares of the company’s stock, valued at $6,651,860. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 53,074 shares of company stock valued at $4,737,245. Insiders own 16.60% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Masimo (MASI) Receives Coverage Optimism Rating of 0.19” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this story can be viewed at https://www.thecerbatgem.com/2018/01/04/masimo-masi-receives-coverage-optimism-rating-of-0-19.html.
Masimo Company Profile
Masimo Corporation is a medical technology company that develops, manufactures and markets a range of non-invasive patient monitoring technologies. The Company’s business is Measure-through Motion and Low Perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry.
Receive News & Stock Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related stocks with our FREE daily email newsletter.